Levente Szalardy

List of Publications by Year
in descending order

26	1,026	687363	580821
papers	citations	13 h-index	25 g-index

28	28	28	1950
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 573-595.	2.9	38
2	Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the ATP6V1B2 Gene. Frontiers in Neurology, 2020, 11, 767.	2.4	9
3	Predictors of localization, outcome, and etiology of spontaneous intracerebral hemorrhages: focus on cerebral amyloid angiopathy. Journal of Neural Transmission, 2020, 127, 963-972.	2.8	10
4	A longitudinally extensive H3 K27M-mutant diffuse midline glioma in an elderly patient clinically mimicking central nervous system inflammation: a case report. Folia Neuropathologica, 2020, 58, 377-385.	1.2	1
5	Exploiting the Therapeutic Potential of Endogenous Immunomodulatory Systems in Multiple Sclerosisâ€"Special Focus on the Peroxisome Proliferator-Activated Receptors (PPARs) and the Kynurenines. International Journal of Molecular Sciences, 2019, 20, 426.	4.1	16
6	Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease. Ideggyogyaszati Szemle, 2019, 72, 39-47.	0.7	0
7	Alzheimerâ€™s Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. Journal of Alzheimer's Disease, 2018, 62, 523-547.	2.6	75
8	PACAP and its role in primary headaches. Journal of Headache and Pain, 2018, 19, 21.	6.0	78
9	Non-motor Behavioral Alterations of PGC-1Î±-Deficient Mice â€“ A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression. Frontiers in Behavioral Neuroscience, 2018, 12, 180.	2.0	9
10	Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters, 2017, 651, 128-133.	2.1	9
11	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimerâ€™s Disease: Shortcomings in Prodromal Diagnosis. Journal of Alzheimer's Disease, 2016, 53, 373-392.	2.6	7
12	Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012â€“2015). Expert Opinion on Therapeutic Patents, 2016, 26, 815-832.	5.0	14
13	Investigational Î±-synuclein aggregation inhibitors: hope for Parkinsonâ€™s disease. Expert Opinion on Investigational Drugs, 2016, 25, 1281-1294.	4.1	17
14	Lack of age-related clinical progression in PGC-1Î±-deficient mice â€“ implications for mitochondrial encephalopathies. Behavioural Brain Research, 2016, 313, 272-281.	2.2	11
15	High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. Acta Neurobiologiae Experimentalis, 2016, 76, 176-181.	0.7	7
16	Histopathological comparison of Kearns-Sayre syndrome and PGC-1Î±-deficient mice suggests aÂnovel concept for vacuole formation in mitochondrial encephalopathy. Folia Neuropathologica, 2016, 1, 9-22.	1.2	15
17	Electron Transport Disturbances and Neurodegeneration: From Albert Szent-GyÃ¶rgyiâ€™s Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-19.	4.0	22
18	Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease. Pharmacology Biochemistry and Behavior, 2015, 132, 115-124.	2.9	20

#	Article	IF	Citations
19	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. Journal of Alzheimer's Disease, 2014, 42, S177-S187.	2.6	64
20	B7 Costimulation and Intracellular Indoleamine 2,3-Dioxygenase Expression in Umbilical Cord Blood and Adult Peripheral Blood. Biology of Blood and Marrow Transplantation, 2014, 20, 1659-1665.	2.0	6
21	Kynurenines in the CNS: recent advances and new questions. Nature Reviews Drug Discovery, 2013, 12, 64-82.	46.4	480
22	Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters, 2013, 554, 131-134.	2.1	22
23	Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosisâ€“osteopontin as a potential marker of clinical severity. Journal of the Neurological Sciences, 2013, 331, 38-42.	0.6	52
24	Neuropathology of Partial PGC-1Î± Deficiency Recapitulates Features of Mitochondrial Encephalopathies but Not of Neurodegenerative Diseases. Neurodegenerative Diseases, 2013, 12, 177-188.	1.4	17
25	Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. Ideggyogyaszati Szemle, 2013, 66, 407-14.	0.7	2
26	Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Current Topics in Medicinal Chemistry, 2012, 12, 1797-806.	2.1	25